Nan Fung Trinity HK Ltd. Invests $2.04 Million in Kura Oncology, Inc. $KURA

Nan Fung Trinity HK Ltd. purchased a new stake in Kura Oncology, Inc. (NASDAQ:KURA) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 230,880 shares of the company’s stock, valued at approximately $2,043,000.

Other institutional investors have also recently bought and sold shares of the company. Arizona State Retirement System lifted its stake in shares of Kura Oncology by 15.8% in the third quarter. Arizona State Retirement System now owns 20,481 shares of the company’s stock valued at $181,000 after buying an additional 2,802 shares in the last quarter. Foundations Investment Advisors LLC bought a new position in Kura Oncology in the 3rd quarter valued at about $254,000. Sector Gamma AS acquired a new position in Kura Oncology during the 3rd quarter valued at about $3,880,000. NorthCrest Asset Manangement LLC bought a new stake in Kura Oncology during the 3rd quarter worth approximately $173,000. Finally, Wealth Enhancement Advisory Services LLC raised its stake in shares of Kura Oncology by 60.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 91,055 shares of the company’s stock worth $859,000 after purchasing an additional 34,143 shares during the last quarter.

Kura Oncology Stock Performance

NASDAQ KURA opened at $8.12 on Friday. The company has a market capitalization of $706.60 million, a PE ratio of -3.27 and a beta of 0.25. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.12 and a current ratio of 5.12. Kura Oncology, Inc. has a 52-week low of $5.41 and a 52-week high of $12.49. The company has a 50-day simple moving average of $10.15 and a 200 day simple moving average of $9.05.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. The company had revenue of $20.75 million during the quarter, compared to analysts’ expectations of $17.48 million. On average, research analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on KURA. UBS Group lifted their target price on Kura Oncology from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, November 14th. Wedbush reaffirmed an “outperform” rating and set a $38.00 price objective (up from $36.00) on shares of Kura Oncology in a report on Friday, November 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research note on Thursday, January 22nd. Leerink Partners set a $20.00 price target on shares of Kura Oncology and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Finally, Citigroup restated a “market outperform” rating on shares of Kura Oncology in a report on Friday, December 5th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $28.00.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, insider Teresa Brophy Bair sold 11,208 shares of the firm’s stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $94,819.68. Following the completion of the sale, the insider directly owned 226,931 shares of the company’s stock, valued at $1,919,836.26. This trade represents a 4.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Brian T. Powl sold 8,887 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $11.18, for a total value of $99,356.66. Following the completion of the sale, the insider owned 139,689 shares in the company, valued at approximately $1,561,723.02. The trade was a 5.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 104,411 shares of company stock valued at $1,035,994 in the last quarter. Insiders own 6.40% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.